Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 2680 dose-ranging study in idiopathic hypersomnia
2025-520981-23-00Phase 2Authorised
- Sponsor
- Alkermes
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of alixorexton in hypersomnolence disorder (4 arms), sponsored by Alkermes. Primary endpoint: Change in Epworth Sleepiness Scale from baseline to Week 8. Planned start Aug 2025; status: authorised.
02
Drugs
alixorexton
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on 2025-520981-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520981-23-00.